Abstract
Nanomaterials have received considerable attention due to their unique properties; they have high surface area compared to volume ratio, giving them superior chemical, optical and thermal characteristics. Nanomaterials have also both diagnostic and therapeutic applications. In this mini review, we are highlighting valuable data about human immunodeficiency virus (HIV), its relationship with cancer and its potential treatment with some nanomaterials such as silver nanoparticles (Ag NPs).
Similar content being viewed by others
References
J. Takehisa, et al. (1998). Various types of HIV mixed infections in Cameroon. Virology 245, (1), 1–10.
P. Piot (2006). AIDS: from crisis management to sustained strategic response. Lancet 368, (9534), 526–530.
Control, C.f.D. (1987). Recommendations for prevention of HIV transmission in health-care settings. MMWR Suppl. 36, 1S–18S.
W. Rozenbaum, et al. (1988). HIV transmission by oral sex. Lancet 1, (8599), 1395.
G. M. Shaw and E. Hunter (2012). HIV transmission. Cold Spring Harb. Perspect. Med. 2, a006965.
S. Mahalingam, et al. (2002). The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses. J. Leukoc. Biol. 72, (3), 429–439.
K. Balabanian, et al. (2004). CXCR7-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. J. Immunol. 173, (12), 7150–7160.
S. Y. Park, et al. (2011). Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus. Nucleic Acid Ther. 21, (6), 395–402.
E. J. Platt, J. P. Durnin, and D. Kabat (2005). Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 79, (7), 4347–4356.
D. M. Eckert and P. S. Kim (2001). Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, (1), 777–810.
W. E. Johnson and J. M. Coffin (1999). Constructing primate phylogenies from ancient retrovirus sequences. Proc. Natl. Acad. Sci. 96, (18), 10254–10260.
U. Scherdin, K. Rhodes, and M. Breindl (1990). Transcriptionally active genome regions are preferred targets for retrovirus integration. J. Virol. 64, (2), 907–912.
A. R. Schröder, et al. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, (4), 521–529.
R. S. Mitchell, et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, (8), e234.
J. Martin-Serrano, T. Zang, and P. D. Bieniasz (2003). Role of ESCRT-I in retroviral budding. J. Virol. 77, (8), 4794–4804.
P. D. Bieniasz (2006). Late budding domains and host proteins in enveloped virus release. Virology 344, (1), 55–63.
J. E. Garrus, et al. (2001). Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107, (1), 55–65.
J. Martin-Serrano, T. Zang, and P. D. Bieniasz (2001). HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7, (12), 1313.
T. Zhu, et al. (1993). Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261, (5125), 1179–1181.
Z. Smit-McBride, et al. (1998). Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4+ T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol. 72, (8), 6646–6656.
G. Pantaleo, et al. (1993). HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, (6418), 355.
J. Oleske, R. Kapila, and M. Reichman (1986). Acquired immunodeficiency syndrome (AIDS). Jama 256, 362–366.
L. Kumaranayake and C. Watts (2001). Resource allocation and priority setting of HIV/AIDS interventions: addressing the generalized epidemic in sub-Saharan Africa. J. Int. Dev. J. Dev. Stud. Assoc. 13, (4), 451–466.
Control, C.f.D. and Prevention (2001). Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep. 50, (RR-19), 1.
M. S. Cohen, et al. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, (6), 493–505.
I. Abdelrahman (2015). Induction of P3NS1 myeloma cell death and cell cycle arrest by simvastatin and/or γ-radiation. Asian Pac. J. Cancer Prev. 16, 7103–7110.
L. S. Park, et al. (2018). Association of viral suppression with lower aids-defining and non-aids-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann. Intern. Med. 169, (2), 87–96.
R.-D. Liu, et al. (2014). Mechanism and factors that control HIV-1 transcription and latency activation. J. Zhejiang Univ. Sci. B 15, (5), 455–465.
M. S. Shiels, et al. (2018). Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the united states through 2030. Ann. Intern. Med. 168, (12), 866–873.
S. H. Omland, et al. (2018). Risk of skin cancer in patients with HIV: a Danish nationwide cohort study. J. Am. Acad. Dermatol. 79, (4), 689–695.
S. N. Akarolo-Anthony, et al. (2014). Cancer burden among HIV-positive persons in Nigeria: preliminary findings from the Nigerian AIDS-cancer match study. Infect. Agents Cancer 9, (1), 1.
N. Abdel-Tawab, D. Oraby, S. Saher, S. Ismail (2016). Understanding HIV-related vulnerability and stigma among Egyptian youth. Cairo: Population Council – Egypt Office. https://www.popline.org/node/650620.
T. K. Vyas, L. Shah, and M. M. Amiji (2006). Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv. 3, (5), 613–628.
J. das Neves, et al. (2010). Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Deliv. Rev. 62, (4–5), 458–477.
P. Sharma and S. Garg (2010). Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv. Drug Deliv. Rev. 62, (4–5), 491–502.
R. Parboosing, et al. (2012). Nanotechnology and the treatment of HIV infection. Viruses 4, (4), 488.
M.-C. Bowman, et al. (2008). Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 130, (22), 6896–6897.
M. P. de Oliveira, et al. (2005). Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 mice. Pharm. Res. 22, (11), 1898–1905.
R. H. Müller, S. Gohla, and C. M. Keck (2011). State of the art of nanocrystals—special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. 78, (1), 1–9.
B. E. Rabinow (2004). Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, (9), 785.
A. L. Pozniak, et al. (2010). Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. Aids 24, (1), 55–65.
R. Schrijvers, B. A. Desimmie, and Z. Debyser (2011). Rilpivirine: a step forward in tailored HIV treatment. Lancet 378, (9787), 201–203.
C. Villalonga-Barber, et al. (2008). Dendrimers as biopharmaceuticals: synthesis and properties. Curr.Top. Med. Chem. 8, (14), 1294–1309.
Y. Pellequer and A. Lamprecht Nanoscale Cancer Therapeutics: Drug Delivery Concepts in Nanoscience (Pan Stanford Publishing Pte. Ltd., Singapore, 2009).
C. K. Leonard, et al. (1990). Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265, (18), 10373–10382.
A. I. El-Batal, et al. (2018). Biogenic synthesis of copper nanoparticles by natural polysaccharides and Pleurotus ostreatus fermented fenugreek using gamma rays with antioxidant and antimicrobial potential towards some wound pathogens. Microb. Pathog. 118, 159–169.
M.A. Elkodous, et al. (2018). C-dots dispersed macro-mesoporous TiO2 phtocatalyst for effective waste water treatment. Charact. Appl. Nanomater. 1, (2), 1–9. https://doi.org/10.24294/can.v1i2.585.
K. Pal, et al. (2018). Soft, self-assembly liquid crystalline nanocomposite for superior switching. Electron. Mater. Lett. 15, 84–101.
T. Thirugnanasambandan, et al. (2018). Aggrandize efficiency of ultra-thin silicon solar cell via topical clustering of silver nanoparticles. Nano Struct. Nano Objects 16, 224–233.
F. M. Mosallam, et al. (2018). Biomolecules-mediated synthesis of selenium nanoparticles using Aspergillus oryzae fermented Lupin extract and gamma radiation for hindering the growth of some multidrug-resistant bacteria and pathogenic fungi. Microb. Pathog. 122, 108–116.
K. Pal, M. A. Elkodous, and M. L. N. M. Mohan (2018). CdS nanowires encapsulated liquid crystal in-plane switching of LCD device. J. Mater. Sci. Mater. Electron. 29, (12), 10301–10310.
A. I. El-Batal, F. M. Mosallam, and G. S. El-Sayyad (2018). Synthesis of metallic silver nanoparticles by fluconazole drug and gamma rays to inhibit the growth of multidrug-resistant microbes. J. Clust. Sci. 29, (6), 1003–1015.
G. S. El-Sayyad, F. M. Mosallam, and A. I. El-Batal (2018). One-pot green synthesis of magnesium oxide nanoparticles using Penicillium chrysogenum melanin pigment and gamma rays with antimicrobial activity against multidrug-resistant microbes. Adv. Powder Technol. 29, (11), 2616–2625.
J. L. Elechiguerra, et al. (2005). Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnol. 3, (1), 6.
H. H. Lara, et al. (2011). Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. J. Nanobiotechnol. 9, (1), 38.
L. Singh, H. G. Kruger, G. E. M. Maguire, T. Govender, and R. Parboosing (2017). The role of nanotechnology in the treatment of viral infections, Ther. Adv. Infect. Dis. 4, (4), 105–131. https://doi.org/10.1177/2049936117713593.
UNAIDS (2018). http://www.unaids.org/en/resources/documents/2018/unaids-data-2018.
NIAID (2018). https://www.niaid.nih.gov/research/advances-2018.
R. Yarchoan, and T. S. Uldrick (2018). HIV-Associated Cancers and Related Diseases. N. Engl. J. Med. 378, 1029–1041. https://doi.org/10.1056/NEJMra1615896.
Acknowledgments
The authors would like to thank the Nanotechnology Research Unit (P.I. Prof. Dr. Ahmed I. El-Batal), Drug Microbiology Lab., Drug Radiation Research Department, NCRRT, Egypt, for financing and supporting this study under the project “Nutraceuticals and Functional Foods Production by using Nano/ Biotechnological and Irradiation Processes”.
Funding
Not applicable.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving Human Participation and/or Animals
This article does not contain any studies with human and/or animals performed by any of the authors.
Informed consent
Not applicable.
Ethical approval
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Abd Elkodous, M., El-Sayyad, G.S., Nasser, H.A. et al. Engineered Nanomaterials as Potential Candidates for HIV Treatment: Between Opportunities and Challenges. J Clust Sci 30, 531–540 (2019). https://doi.org/10.1007/s10876-019-01533-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10876-019-01533-8